- CAY10566
-
- $47.00 / 1mg
-
2024-11-19
- CAS:944808-88-2
- Min. Order:
- Purity: 99.54%
- Supply Ability: 10g
- CAY10566
-
- $47.00 / 1mg
-
2024-11-19
- CAS:944808-88-2
- Min. Order:
- Purity: 99.54%
- Supply Ability: 10g
|
| | CAY10566 Basic information |
| Product Name: | CAY10566 | | Synonyms: | 3-[4-(2-CHLORO-5-FLUOROPHENOXY)-1-PIPERIDINYL]-6-(5-METHYL-1,3,4-OXADIAZOL-2-YL)-PYRIDAZINE;CAY10566;2-(6-(4-(2-CHLORO-5-FLUOROPHENOXY)PIPERIDIN-1-YL)PYRIDAZIN-3-YL)-5-METHYL-1,3,4-OXADIAZOLE;Pyridazine, 3-[4-(2-chloro-5-fluorophenoxy)-1-piperidinyl]-6-(5-methyl-1,3,4-oxadiazol-2-yl)-;Inhibitor,inhibit,Stearoyl-CoA Desaturase (SCD),CAY10566,CAY 10566,CAY-10566;CAY 10566, SCD1 inhibitor;CAY10566, 10 mM in DMSO | | CAS: | 944808-88-2 | | MF: | C18H17ClFN5O2 | | MW: | 389.81 | | EINECS: | | | Product Categories: | | | Mol File: | 944808-88-2.mol |  |
| | CAY10566 Chemical Properties |
| Melting point | 160 - 170°C | | Boiling point | 600.2±65.0 °C(Predicted) | | density | 1.369±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 2.01±0.10(Predicted) | | form | Solid | | color | Pale Beige |
| | CAY10566 Usage And Synthesis |
| Description | Stearoyl-CoA desaturase (SCD) catalyzes the committed step of the conversion of saturated, long-chain fatty acids to monounsaturated fatty acids. The SCD1 gene is thought to play a key role in lipid homeostasis and body weight regulation. Thus, modulating SCD1 activity pharmacologically may be a useful tool for regulating type 2 diabetes, dyslipidemia, and obesity. CAY10566 is a potent and selective inhibitor of SCD1 that demonstrates IC50 values of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. This compound inhibits the conversion of saturated, long-chain fatty acyl-CoAs to monounsaturated, long-chain fatty acyl-CoAs in HepG2 cells with IC50 values of 7.9 and 6.8 nM, respectively, when heptadecanoic acid and palmitic acid are used as the substrate. | | Uses | CAY10566, is a stearoyl-CoA desaturase (SCD) inhibitor. | | in vivo | After establishment of palpable tumors, the mice are treated with vehicle or SCD1 inhibitor (2.5 mg/kg CAY10566 orally twice daily). The effect of SCD1 inhibition on the Akt-driven tumors is greater than on the Ras-driven tumors, with the mean tumor volume at day 13 or 14 post therapy, relative to untreated tumors, 0.5±0.04 and 0.67±0.05 respectively (P=0.01 for Ras-Akt comparison, by two-tailed t test)[4]. |
| | CAY10566 Preparation Products And Raw materials |
|